Frazier Life Sciences Management, L.P.
Q3 2024 13F-HR Holdings
Net value change ($000)
+357,345
(16.7%)
New positions
8
Sold out positions
4
Turnover %
10.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2024
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| MBX | 155,499 | NEW |
| PHAT | 78,650 | 75.5% |
| VRNA | 49,431 | 103.1% |
| MIRM | 34,168 | 15.4% |
| RYTM | 29,258 | 30.0% |
| PCVX | 22,005 | 28.0% |
| ASND | 19,908 | NEW |
| ANAB | 19,738 | 36.4% |
| RARE | 17,735 | 101.5% |
| ALKERMES PLC | 16,126 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| HilleVax, Inc. | -134,837 | -87.8% |
| NAMS | -21,484 | -9.1% |
| PEPG | -17,976 | -74.9% |
| Cerevel Therapeutics Holdings, Inc. | -16,070 | -100.0% |
| APLT | -10,676 | -100.0% |
| RCKT | -6,173 | -18.4% |
| ANTX | -4,491 | -100.0% |
| Elevation Oncology, Inc. | -4,392 | -55.0% |
| Merus N.V. | -3,436 | -15.6% |
| MGNX | -2,891 | -22.6% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|